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1. Introduction 
This chapter discusses the role of cell cycle machinery in initiation and progression of 
pancreatic cancer. Normal pancreatic cells—their types, organization, and functions—are 
first described to characterize the environment in which cellular transformation and tumor 
expansion occurs. The epidemiology and histology of pancreatic cancer is then briefly 
presented to emphasize the urgent need for earlier diagnosis and more effective treatments. 
Current efforts towards this goal are focused on understanding the disease at the molecular 
level, so the hallmarks of cancerous cells are discussed with respect to the progression 
model of pancreatic cancer development. Because the pancreas is composed of various cell 
types with different genetic backgrounds and regulatory systems, identifying the cell in 
which cancer originates is of utmost importance. Molecular mechanisms of normal 
proliferative control are then presented so that mechanisms by which they are disrupted can 
be appreciated. Particular attention is paid to how signaling transduction pathways and the 
cell cycle machinery cooperate to make cell fate decisions at the Restriction point. This 
analysis sets the stage for evaluating the role of cell cycle control mechanisms in 
transformation of the initiating cell in pancreatic cancer. The chapter concludes by arguing 
that genetic alterations associated with pancreatic cancer indicate disrupted cell cycle 
control mechanisms play a central role in disease development and progression. 
2. Pancreatic tissue organization and cellular function 
Evaluating the role of cell cycle machinery in pancreatic cancer requires understanding the 
architecture and cellular organization of this dual-function gland. The pancreas is an 
approximately six inch long cylindrical organ in the abdomen, located between the stomach 
and the spine (Romer & Parsons, 1977). 
The endocrine component is composed of clusters of alpha, beta, and PP (pancreatic 
peptide) cell types that form structures called the islets of Langerhans (Jain & Lammert, 
2009). These cells produce metabolic hormones involved in energy metabolism. Major cell 
types and their organization are summarized in Figure 1.  
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Fig. 1. Global View of Pancreas. The pancreas is located in the abdomen behind the 
stomach. It is composed of four areas: The head, neck, body, and tail. It is comprised of two 
types of parenchymal tissue: The islets of Langerhans, composed of alpha, beta, and gamma 
cells are in charge of endocrine signal and hormone detection, while the pancreatic ancine 
are in charge of exocrine signaling and production of digestive enzymes. 
It plays major roles in the vertebrate hormonal (endocrine) and digestive (exocrine) systems 
(Jain & Lammert, 2009, Means & Leach, 2001). The pancreas contains two different types of 
parenchymal (i.e. functional) tissue that is of endodermal origin (Gittes, 2009). Most of its 
mass is clustered acinar cells that synthesize digestive pro-enzymes (Means & Leach, 2001). 
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The most prevalent type of pancreatic cancer is infiltrating ductal adenocarcinoma, which 
appears to initiate in distinct subsets of cells within the exocrine tissue (Maitra, A & Hruban, 
2008). However, other cell types can participate and/or be affected by the disease. This 
includes “enabling cells”, which are local, untransformed populations that can contribute to 
disease development. Pancreatic stellate cells, for instance, are stromal cells recruited by the 
tumor to help create an environment promoting disease progression (Vonlaufen, et al., 2008).  
2.1 Endocrine function 
Endocrine function is mediated by groups of cells called the islets of Langerhans, which 
secrete essential peptide hormones regulating energy metabolism into the bloodstream (Jain 
& Lammert, 2009). The pancreas contains approximately 1 million of these cell clusters, each 
composed of four different cell types distinguished by their secretatory role. The alpha and 
beta cells work together to maintain blood sugar levels. Alpha cells produce glucagon to 
promote release of stored glucose in response to an unfed state (Gromada, et al., 2007). In 
contrast, β cells generate insulin in response to eating so that incoming glucose can be 
utilized by body tissues (Collombat, et al., 2010). These functionalities are fine-tuned by 
somatostatin secreted from δ cells (Brink, 2003). PP cells are so called because they produce 
pancreatic polypeptide that helps regulate endocrine and exocrine secretions, control 
hepatic glycogen levels, and participate in regulation of gastrointestinal secretions 
(Lonovics, et al., 1981). Insulin and glucagon are rapidly disseminated by a capillary 
network that is connected to blood vessels via layers of endocrine cells (Jain & Lammert, 
2009, Means & Leach, 2001). Less than 10% of pancreatic cancers originate in endocrine cells. 
Nevertheless, these cells could play an important secondary role in more common ductal 
adenocarcinomas via their ability to produce hormones affecting cell fate decisions. In 
addition, their extensive capillary network could be exploited by metastasizing tumor cells. 
2.2 Exocrine function 
The majority of pancreatic cancers (>90%) are infiltrating ductal adenocarcinomas of the 
exocrine system (Maitra, A & Hruban, 2008). Thus, identifying the potential cell types 
involved and their normal function is essential for evaluating how cell cycle machinery 
contributes to cancer development. Exocrine function is mediated by clusters of acinar cells 
(called acinus) that secrete bicarbonate ions and digestive pro-enzymes (Means & Leach, 
2001). These products are transported in the pancreatic juice to the duodemun by a ductal 
system lined with a layer of mucinous columnar epithelial cells. Exocrine function is under 
control of the hormones gastrin, cholecystokinin and secretin, which are secreted by 
gastrointestinal cells in response to physical distension and food intake (Jean, 2008).  
The alkaline bicarbonate secreted by centroacinar cells regulates pH in the small intestine by 
neutralizing the acidic chyme arriving from the stomach (Freedman & Scheele, 1994). 
Centroacinar cells also secrete mucins, a family of high-molecular-weight, heavily 
glycosylated proteins known primarily for forming biological gels (Nagata, et al., 2007). 
They are involved in signaling, barrier formation, lubrication, and the immune response via 
binding and/or blocking pathogens (Hollingsworth & Swanson, 2004). Overexpression of 
mucin proteins (e.g. MUC1) occurs in many different types of cancers, including pancreatic 
(Moniaux, et al., 2004). Based on their unique genetic background, centroacinar cells have 
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been implicated as the potential cell of origin giving rise to ductal adenocarcinomas (Singer 
& Niebergall-Roth, 2009, Stanger & Dor, 2006).  
Digestive pro-enzymes for breaking down fats and protein are secreted into the lumen of 
the acinus by basophilic cells, so-called because they tend to stain intensely with basic dyes 
(Singer & Niebergall-Roth, 2009). These cells contain large cytoplasmic secretory granules in 
which digestive pro-enzymes are maintained in an inactive state, a method of regulatory 
control that is essential to prevent auto-degradation of the cell and subsequent development 
of a condition called acute pancreatitis (Waldthaler, et al., 2010). This type of cellular damage 
increases the risk of pancreatic cancer, an observation that provides insight into identity of 
the originating cell and how it is transformed (Suda, et al., 2007). 
3. Pancreatic cancer 
Epidemiology studies have revealed pancreatic cancer runs in some families and is 
associated with specific genetic mutations (Chakraborty, et al., 2011, Greer, et al., 2009, 
Lowenfels & Maisonneuve, 2006, Shi, et al., 2009). As is the case for all cancers, pancreatic 
cancer arises when a normal cell is transformed by accumulated genetic alterations into a 
cancer cell that seeks to duplicate itself at the expense of the organism. If this transformed 
cell can escape internal and external fail-safe mechanisms, obtain nutrients, and successfully 
activate its proliferative program, it can eventually form a more complex mass of cancerous 
cells. Continued growth of the tumor depends on space availability and promoting growth 
of blood vessels (angiogenesis) to supply nutrients and remove waste. Further tumor 
growth can result in loss of pancreatic function, impairment of local blood vessels and 
organs, and finally metastasis and secondary tumor formation at distal parts of the body. An 
unfortunate characteristic of pancreatic cancer is its propensity for metastasis early in tumor 
growth, which is likely responsible in part for its aggressive nature (Bardeesy & DePinho, 
2002). 
Pancreatic cancer is not exceptionally rare, with approximately 43,000 cases in 2010, making 
it the tenth-most-common form of the disease (ACS, 2007, ACS, 2010, NCI, 2010). However, 
37,000 of those died, illustrating its high mortality rate and ranking pancreatic cancer as the 
fourth leading cause of cancer fatalities worldwide (ACS, 2007, ACS, 2010, NCI, 2010). The 
lack of early symptoms results in delayed diagnosis and a higher likelihood of metastasis, 
thus dramatically limiting treatment options and outcome (Hansel, et al., 2003). The percent 
of patients alive one year after diagnosis is about 25%, while the five year rate is a 
depressing 6% (Hariharan, et al., 2008). The five year survival increases substantially with 
early detection and surgical removal of the tumor (approximately 22%), emphasizing the 
importance of developing better diagnostic tools and markers (Benson, et al., 2010). Even 
with early detection and conventional treatment, however, pancreatic cancer is still quite 
deadly. The ineffectiveness of standard therapy suggests its development and 
aggressiveness might involve unique molecular features.  
The pancreas is composed of head, body, and tail sections, with cancer most commonly 
occurring in the head region (see Figure 1) (Romer & Parsons, 1977). The majority of cases 
are malignant adenocarcinomas arising in the exocrine component (Maitra, A & Hruban, 
2008). Typically, the cancer initiates in the pancreatic ducts (infiltrating ductal 
adenocarcinoma), or less frequently in the acini (acinar adenocarcinoma). It presents as a 
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dense mass with crennolated extensions into surrounding tissue. Histological analysis 
reveals a neoplastic epithelium composed of poorly differentiated, gland-forming cells that 
illicit a very strong growth of fibrous and/or connective tissue around the neoplaisa (i.e. a 
desmoplastic reaction) (Hartel, et al., 2004, Maitra, Anirban, et al., 2006). A much smaller 
subset of exocrine pancreatic tumors present as adenosquamous carcinomas, squamous cell 
carcinomas, and giant cell carcinomas (Hruban & Zamboni, 2009). Metastatic endocrine 
cancers (also called islet cell tumors) are much less common and only account for 
approximately 1% of pancreatic cancers (Spiegel & Libutti, 2010).  
3.1 Molecular events underlying cellular transformation 
Cancers are recognized as such despite diverse physiological presentation because they all 
share a limited set of underlying causative characteristics. These so-called “hallmarks of 
cancer” are the distillation of extensive efforts to understand how a normal cell is 
transformed into a cancerous version (Hanahan & Weinberg, 2000).  
 
Fig. 2. Hallmarks of Cancer. Genetic insults to the pancreatic cells can result in the 
accumulation of the six hallmarks associated with cancer. The relative percentage of 
transformed cells types in the pancreas is also shown. 
For this reason they are the predominant paradigm for understanding its molecular basis 
and developing better diagnostics and treatments. In order to evaluate how disrupted cell 
cycle control specifically contributes to pancreatic cancer, it is first necessary to appreciate 
why it has been designated as a fundamental hallmark of the disease.  
3.2 Hallmarks of cancer 
Normal cells perform specific tasks and exist for the greater good of the organism. For this 
reason, their proliferative capability is a double-edged sword that must be highly 
constrained by internal checkpoints and external signals from other cells or the 
microenvironment (Bogenrieder & Herlyn, 2003). Cancer cells evade these constraints via 
accumulated genetic alterations, resulting in a selfish cell whose allegiance is now to its own 
survival and expansion. A multi-cellular organism protects itself by making cell duplication 
dependent on externally generated signals. Positive growth-promoting factors are required 
for proliferation while negative growth-inhibitory factors must be withdrawn. Two 
hallmarks of cancer are therefore self-sufficiency in growth signals (i.e. cell division in the 
absence of mitogenic factors) and insensitivity to growth-inhibitory factors (i.e. cell division 
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despite the presence of anti-mitogenic signals) (Hanahan & Weinberg, 2000). Extensive 
analysis of cell signaling pathways has identified myriad ways in which genetic alterations 
can satisfy these two criteria (Brognard & Hunter, 2011). Typically, multiple biological 
targets must be compromised due to redundancies and control mechanisms that evolved to 
prevent deregulated signaling.  
Self-sufficiency in growth signals and insensitivity to growth-inhibitory factors is not 
sufficient to generate a transformed cell capable of tumor formation. Most cells have an 
internal clock that limits their replicative potential so that they can only duplicate a fixed 
number of times before entering a senescent or non proliferative state (Hornsby, 2005). As 
will be discussed in more detail below, stem cells (and cell populations with stem cell-like 
characteristics) are an important exception to this rule and likely play a central role in the 
initiation of pancreatic cancer. The mechanism of this clock centers on telomere 
maintenance, the process whereby chromosome ends are protected from degradation (Yang, 
Q., 2008). Loss of telomere protection occurs after a fixed number of duplications, sending a 
signal that causes cells to exit the proliferative cycle and enter a senescent state (Yibin, et al., 
2008). Cancer cells typically overcome this internal checkpoint—for instance by 
hyperactivation of the telomere synthesizing enzyme telomerase—to acquire the 
proliferative capacity needed for tumor formation (Artandi & DePinho, 2010). Telomere 
maintenance is also disrupted in pancreatic cancer, but in a complex manner that varies 
with disease progression (van Heek, et al., 2002). This pattern provides insight into its 
origins and development. 
Cells have additional mechanisms to prevent inappropriate proliferation and mount a 
protective response should it occur. In the event of irreparable damage or grow-promoting 
mutations, for example, the cell can initiate an apoptotic pathway resulting in its death and 
deconstruction (Wyllie, 2010). A major hallmark of cancer is, thus, evasion of apoptosis 
(Hanahan & Weinberg, 2000).  
Once immortalized, the transformed cell can proliferate and begin to generate cancer cells, 
comprising the bulk of the tumor. However, cellular expansion can only occur up to a 
certain point as determined by available space and nutrients. A hallmark of cancer is, 
therefore, formation of new blood vessels (angiogenesis) so nutrients can be obtained and 
delivered throughout the tumor and so waste products can be removed (Hanahan & 
Weinberg, 2000). As a result, the tumor can further increase in size and complexity, 
compromising not only the affected organ itself but also nearby blood vessels and tissues.  
The final hallmark of cancer is perhaps most responsible for threatening organism survival. 
Even with angiogenesis, tumor size will eventually be constrained by physical barriers. As a 
consequence, the tumor is subjected to selective pressure, driving invasion of surrounding 
tissue and metastasis to distal locations (Hanahan & Weinberg, 2000). In this process, cancer 
cells detach from the primary tumor and secrete enzymes (e.g. MMPs) that allow passage 
through the extracellular matrix (Singh, et al., 2002). They can then migrate and start 
secondary tumors in surrounding tissue or in distal areas by commuting through the body’s 
highways (lymph and hematopoietic systems). Once a tumor has metastasized, the potential 
for successful therapeutic intervention is severely reduced, as is the case with pancreatic 
cancer (Bardeesy & DePinho, 2002).  
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3.3 Progression model of pancreatic cancer development  
The current view of pancreatic cancer development is summarized in a progression model 
wherein the temporally ordered accumulation of genetic mutations drive transitions 
through a series of pre-cancerous legions culminating with infiltrating ductal 
adenocarcinoma (in the majority of cases) (Koorstra, et al., 2008a). These steps were defined 
by histology of precancerous lesions at various stages that are collectively described as 
pancreatic intraepithelial neoplasias (PanINs) (Koorstra, et al., 2008b). They are further 
subdivided into PanIN-1A, PanIN-1B, and PanIN-2/3 based on distinct histology and 
genetic background (Koorstra, et al., 2008b, Koorstra, et al., 2008a). PanINs present as 
microscopic lesions situated in the smaller pancreatic ducts (Maitra, Anirban, et al., 2005). 
Genetic analysis of these distinct cell populations revealed ordered accumulation of 
alterations associated with the more advanced adenocarcinoma (Koorstra, et al., 2008a). The 
types of genetic insults present in pancreatic cancer are quite diverse and include large 
chromosomal alterations such as breaks, duplications, deletions, fusions, and translocations 
(Campbell, et al., 2010). There is also CpG island methylation of promoters, telomere 
disruptions, and microsatellite instability, along with specific mutations in important 
oncogenes and tumor suppressors (Lin, et al., 2011, López-Casas & López-Fernández, 2010, 
Welsch, et al., 2007). Precursor lesions display an increasing proliferation rate as they 
progress towards an adenocarcinoma (Koorstra, et al., 2008b). 
From a molecular biology perspective, three pertinent questions are: 1) What type of cell 
undergoes transformation? 2) What genetic elements are disrupted? 3) What biological 
activities are compromised and how do they contribute to transformation? Each of these 
questions will be addressed, with particular emphasis on the role of cell cycle machinery. 
The first task is to consider the cell type in which pancreatic cancer originates, since its 
genetic makeup and regulatory systems will dictate how to interpret genetic alterations 
associated with the disease.  
3.4 Identity of the cell initiating tumor formation 
Identifying the cell in which cancer originates is essential for understanding the 
consequences of genetic alterations and their effect on cell cycle control. This initiating cell 
has not yet been definitively described, but we can speculate it accumulates genetic 
mutations that, if not resolved (via repair or cell death), culminate in the hallmarks of 
cancer. The average age of onset for infiltrating ductal adenocarcinoma is approximately 73 
years, indicating it develops in the mature organ (Greer, et al., 2009, Lowenfels & 
Maisonneuve, 2006). One obvious candidate for transformation is the differentiated acinar 
ductal cell itself, which could be induced to re-enter the cell cycle and proliferate in 
opposition to internal and environmental cues. Such a transition seems quite daunting, 
because the mature cell must first de-differentiate to a more primitive state with 
proliferative capacity via genomic reorganization and altered gene expression. Secondly, 
this reverted cell must be induced to proliferate inappropriately, which likely requires 
disruption of different biological pathways. Thirdly, it is likely that fail-safe systems unique 
to each transition would have to be inactivated. Despite these hurdles, centroacinar cells are 
a possible candidate because they reside at the junction between acini and ducts and are the 
only differentiated cells in the developed pancreas with activated signaling pathways 
associated with proliferation (Miyamoto, et al., 2003). Thus, fewer genetic changes might be 
required in this background to generate the initiating transformed cell.  
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An alternative possibility is that cancer arises from transformation of a pancreatic stem cell. 
This model posits that the originating cell in cancer development is either a stem cell or has 
stem cell-like characteristics (Stanger & Dor, 2006). Their defining feature is unlimited self-
renewal capabilities. Normal stem cells play key roles in development and tissue 
maintenance by dividing asymmetrically to give one progeny with self-renewing capacity 
and another that commits to a differentiation pathway (Leeb, et al., 2011). Cancer stem cells 
are thought to follow the same process, except that their asymmetrical division generates 
cancer cells comprising the bulk of the tumor (Clevers, 2011, Stanger & Dor, 2006). 
Transformation of a cell with proliferative capacity seems more likely because it already 
exhibits one or more of the hallmarks of cancer. Evidence suggests that stem cells only make 
up 0.1-1% of the tumor cell population and show greater resistance to chemotherapy and 
radiation compared to their progeny (Bomken, et al., 2010). Consistent with this idea, 
subpopulations of pancreatic cancer cells have been isolated that can initiate a new tumor 
when implanted in mice (Reya, et al., 2001). Given that disease arises in the mature organ, a 
likely candidate for initial transformation would be a pancreatic adult stem cell. Such a cell 
type has not yet been identified, but their presence in other organs makes a pancreatic 
version a distinct possibility (Li, et al., 2007). These observations could help explain the well-
known unresponsiveness of pancreatic cancer to traditional chemotherapies (Wang, Zhiwei, 
et al., 2011c).  
A third possibility is involvement of what are called facultative progenitor cells located in 
the acinar environment (Leach, 2005). In the case of pancreatic injury (e.g. acute 
pancreatitis), differentiated cells can be recruited back into the proliferative cycle to replace 
old or damaged cells (Raimondi, et al., 2010). Such cells exhibit a more “stem cell-like” 
phenotype and hence are more susceptible to transformation. There is experimental 
evidence supporting this idea. Acute pancreatitis is a risk factor for pancreatic cancer, and, 
in a chemically induced version of this disease, acinar cells de-differentiate to replenish the 
cell supply (Guerra, et al., 2007, Jensen, et al., 2005). In addition, growth-factor stimulation 
can cause acinar cells to undergo an abnormal transdifferentiation event to generate what is 
called an acinar-to-ductal metaplasia (Husain & Thrower, 2009). Taken together, these 
observations strongly implicate facultative progenitors as the initiating cell in pancreatic 
cancer. While further efforts to definitively characterize the relevant cell type are required, 
armed with the above possibilities we can now discuss the basics of proliferative control 
mechanisms and the important role of the cell cycle machinery.  
4. Molecular mechanisms of proliferative control 
The cell cycle is an experimentally based, theoretical construct describing the stages through 
which a cell proceeds to generate a faithful copy of itself (Vermeulen, et al., 2003). These 
discrete steps must be transversed in sequential fashion with DNA replication in S phase 
followed by chromosome segregation and division in M phase. Gap 1 and Gap 2 phases 
separate DNA replication from chromosome segregation. They are also important for 
increasing cell mass (e.g. protein synthesis) and monitoring S and M phases to ensure 
accurate transmission of the genetic material. Progression through the cell cycle is controlled 
by a diverse group of molecular components collectively called the cell cycle machinery 
(Suryadinata, et al., 2010). Disruption of this regulatory network is a fundamental event 
required for the expansion of cancer cells (Hanahan & Weinberg, 2000). Understanding how 
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this machinery functions at the molecular level and is linked to cell fate decisions is 
therefore crucial to evaluating its role in development and progression of pancreatic cancer.  
 
Fig. 3. The Cell Cycle. The stages of the cell cycle (G1, S, G2, M) that take place during the 
duplication of the cell. The Restriction point, the regulatory checkpoint of the cell cycle after 
which the cell is committed to replication is shown, along with the option of senescence. 
4.1 Cell fate decisions 
It is essential to evaluate proliferative capacity within the context of cell function and 
contribution to the organism as a whole. During development, proliferation is transcendent, 
since exponential cell division is required to generate large number of cells. Once maturity is 
reached, proliferative capacity is utilized less frequently (e.g. tissue maintenance and 
repair). A classic example is the hematopoietic system, where immortal stem cells generate 
progeny destined to become distinct functional cells in the blood (Heike & Nakahata, 2004). 
As these cells proceed along differentiation pathways and initiate specific genetic programs, 
their capacity for division diminishes (Congdon & Reya, 2008). External information 
combined with internal preparedness are key components determining cell fate decisions. 
Cell cycle machinery is intimately involved in this process because it coordinates and 
interprets incoming signals to decide whether to proliferate or adopt an alternative fate. This 
decision is called the Restriction point, and its disruption is an essential event in cellular 
transformation (Blagosklonny & Pardee, 2002).  
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A major challenge for the cell is properly interpreting external signals, establishing and 
maintaining connections between signal and cell cycle systems, and maintaining control of 
proliferative potential. For example, withdrawal of growth factors or anti-mitogenic signals 
will cause a tissue culture cell to exit the proliferative cycle and enter a quiescent state 
(Zetterberg, et al., 1995). Such cells can be induced to re-enter the cell cycle by growth factor 
addition, which rapidly activates signal transduction cascades that communicate this 
information to the nucleus (Pomerening, 2009). A key pathway in this regard is Ras/Map 
kinase, which transmits a proliferative signal to the nucleus that jump-starts the cell cycle 
machinery and initiates the gene expression program required for cell duplication (Chang, et 
al., 2003, Coleman, et al., 2004, Takuwa & Takuwa, 2001). In addition, it is imperative that the 
nucleus alert signaling systems that their information has been received and properly acted 
upon. An example of such feedback will be discussed in more detail below. The Ras/Map 
kinase pathway and its regulation of cell cycle machinery play a key role in initiation and 
development of pancreatic cancer (Caldas & Kern, 1995, Moskaluk, et al., 1997). 
Understanding normal functioning of the major cell cycle components and their connection 
to signal transduction pathways is therefore essential to elucidating how and why they are 
disrupted in the disease state.  
4.2 Cell cycle machinery  
Regulation of cell cycle progression is designed to ensure DNA replication and chromosome 
segregation occur in response to the proper signals, proceed in the required temporal order, 
and are carried out accurately (Suryadinata, et al., 2010). The cell cycle machinery that 
control events can be promoters, inhibitors, or evaluators of cell cycle progression but in all 
cases are responsive to internal and extracellular signaling pathways (Novák, et al., 2010). 
The six major types of activity regulated by this machinery include: 1) Establishment of 
ordered biochemical pathways responsible for sequential progression through the cycle; 2) 
Assembly/disassembly of required structures (e.g. formation of DNA origins of replication, 
transcription start sites, chromosome segregation sites, telomeres, etc); 3) Regulation of 
nanomachines controlling production (DNA/RNA polymerases, ribosomes, lipid 
production etc); 4) Communication of outcomes (e.g. informing signaling components that 
transmitted information has been received); 5) Monitoring fidelity of ongoing or completed 
tasks (e.g. mechanisms ensuring cell cycle events are carried out in an accurate and timely 
fashion); 6) Self-regulation of activities (e.g. cell cycle components often regulate themselves 
or each other to drive cell cycle transitions and maintain ordered progression ).  
Cyclin-Dependent Kinases (CDKs) phosphorylate specific protein substrates at 
serine/threonine residues to initiate specific events (e.g. DNA replication) and drive cell 
cycle transitions (Malumbres & Barbacid, 2005). Regulating CDK activity is therefore crucial, 
as indicated by the multiple distinct and redundant pathways controlling its function. The 
CDK subunit alone lacks kinase activity, so it must bind a cell cycle-specific cyclin subunit 
and undergo both phosphorylation and dephosphorylation at unique sites to be activated 
(Harper & Adams, 2001). Functional cyclin-CDK complexes can be inhibited by 
phosphorylation/dephosphorylation, cyclin degradation, and by tight binding of small 
inhibitory proteins such as members of the CIP/KIP family (p21CIP1, p27KIP1 and p57KIP2) and 
the INK family (p15INK4b; p16INK4a; p18INK4c and p19INK4d) (Ekholm & Reed, 2000, Morgan, 
1997, Pavletich, 1999, Sheaff, 1997, Wang, Q., et al., 2011a). The CDK inhibitors are typically 
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thought to function as tumor suppressor proteins (Sherr, C. J. & Roberts, 1995). Genetic 
analysis of pancreatic cancer reveals both cyclin and CDK inhibitors are commonly 
disrupted in the disease, either directly or by alteration of upstream signaling pathways 
(Chen, Jinyun, et al., 2009b, Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a, Lee, et al., 
2009, Schutte, et al., 1997).  
4.3 The restriction point 
The Restriction point represents an operationally defined transition in G1 when the cell 
decides whether to proceed with the proliferative cycle or withdraw and adopt an 
alternative fate (Blagosklonny & Pardee, 2002). The cell cycle machinery makes the decision 
based on evaluation of external signals and internal preparedness. Before the Restriction 
point, cell cycle progression is dependent on mitogen stimulation and thus represents a 
period in which the cell is still receiving information and evaluating its ability to 
successfully divide (Blagosklonny & Pardee, 2002, Sheaff & Roberts, 1998). After the 
Restriction point, cell cycle progression no longer requires growth factor stimulation and the 
cell is committed to completing the proliferative cycle (Blagosklonny & Pardee, 2002, Sheaff 
& Roberts, 1998). Mitogen signaling performs three main functions: 1) It establishes and 
maintains extracellular contact with the cell, transmitting the need for duplication; 2) It 
activates and communicates with cell cycle machinery to drive progression through the 
cycle; and 3) It initiates the gene expression programs required for cell duplication. 
 
Fig. 4. The Ras/Map Pathway. External growth factors bind to the receptor tyrosine kinase 
(RTK) and initiate the transduction of the signal down the protein chain, the end result of 
which is the transcription of factors required for initiation of the cell cycle and cellular 
division. 
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To elucidate the molecular events describing the Restriction point, recall how tissue culture 
cells exit the cell cycle in response to mitogen withdrawal. Re-stimulating these quiescent 
cells with growth factors causes a rapid activation of various signal transduction cascades, 
including the Ras/Map kinase pathway (see Figure 4). In normal cells, this process typically 
involves transient accumulation of active Ras-GTP, which presumably reflects successful 
communication with the nucleus. While growth factor binding to receptor tyrosine kinases 
is responsible for the rapid accumulation of Ras-GTP, it does not explain the transient 
nature of Ras activation. Work from our lab suggests activation of the Map kinase cascade 
initiates a negative feedback loop that indicates successful transmission and so prevents 
further Ras activation (Moeller, et al., 2003).  
 
Fig. 5. CDK2 Regulation. Mitogen stimulation eventually leads to the activation of Cdk2, a 
important late G1 and S phase regulator through the production and subsequent binding of 
cyclins follow by phosphorylation of the complex. Inhibitory signals can lead to 
dephosphorylation of the complex, the degredation of the complex, or it be bound by cyclin 
kinase ihhibitors (CKI). 
Map kinase is translocated into the nucleus, where it initiates transcriptional programs 
required for cell cycling and duplication. It also phosphorylates the CDK2 inhibitor p27kip1, 
resulting in its export from the nucleus. Cytoplasmic p27 targets GRB2 and prevents its 
interaction with the guanine nucleotide exchange factor SOS, thereby preventing formation 
of the GRB2-SOS complex that recruits Ras to the membrane. These observations led us to 
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hypothesize that p27 plays an important role in a negative feedback loop ensuring that: 1) 
The successful transmission of external information to the nucleus is communicated to the 
signaling system; 2) The magnitude and duration of the signal is properly maintained and 
regulated to prevent activation of fail-safe checkpoints and/or hyperproliferation. As will be 
discussed below, our more recent evidence suggests disruption of this pathway could be 
relevant to the initiation and progression of pancreatic tumorigenesis.  
In addition to opening lines of communication, an early response to growth factor 
stimulation is synthesis of cyclin D and activation of CDK4/CDK6 (Ladha, et al., 1998, 
Ohtsubo & Chibazakura, 1996). Cyclin D-CDK4/6 phosphorylates the retinoblastoma 
protein (pRb), a well known tumor suppressor that binds and inhibits the transcription 
factor E2F (Knudsen & Knudsen, 2008). As a result, E2F is released and mediates 
transcription of genes whose products are required for cell cycle progression, mass increase, 
and DNA replication (Chen, Hui-Zi, et al., 2009a, Nevins, 2001). Activity of cyclin D-
CDK4/6 complexes is negatively regulated by the tight binding inhibitor p16 (Sherr, C. J. & 
Roberts, 1999, Wang, Q., et al., 2011a). In pancreatic cancer, cyclin D1 overexpression and 
p16 inactivation are very common events, emphasizing the importance of disrupting G1 
progression to disease development (Chen, Jinyun, et al., 2009b, Fry, et al., 2008, Gansauge, 
et al., 1997, Kornmann, Marko, et al., 1998a, Schutte, et al., 1997). A major goal of E2F 
liberated by cyclin D-CDK4/6 is synthesizing cyclin E, which binds and activates CDK2 to 
continue progression through G1 and prepare for the S phase transition (Roberts & Sherr, 
2003, Sheaff & Roberts, 1998). Cyclin E-CDK2 further phosphorylates pRb and releases E2F 
to make more cyclin E, thus establishing a positive feedback loop. The result is a burst of 
cyclin E-CDK2 activity that is thought to drive the transition from mitogen-dependent to 
mitogen-independent cell cycle progression (Sheaff & Roberts, 1998).  
It will be argued below that compromised Restriction point control is the major focus of 
genetic alterations in pancreatic cancer development. 
Another positive feedback loop is established as cells approach the G1/S phase transition. 
Cyclin E-CDK2 phosphorylates and inactivates its own inhibitor, p27kip1, resulting in a 
burst of cyclin E-CDK2 activity (Sheaff, et al., 1997). As a consequence cyclin A-CDK2 is 
generated to propel cells into S phase and monitor its progression (Woo & Poon, 2003). After 
accomplishing its goals, cyclin E-CDK2 initiates its own destruction by phosphorylating 
cyclin E and targeting it for proteasomal degradation (Clurman, et al., 1996). Once DNA is 
replicated, the cell transitions into G2 where the accuracy of DNA synthesis is evaluated and 
the cell prepares for chromosome segregation (Clarke & Gimenez-Abian, 2000). Cyclin B-
CDK1 is in control during these processes (Kishimoto & Okumura, 1997). After division the 
system resets and cells must again evaluate internal and external signals to decide whether to 
continue the proliferative cycle or withdraw and adopt an alternative fate (Sheaff & Roberts, 
1998). In the case of transformed cells, the default decision is generally proliferation.  
5. Cell cycle machinery in development and progression of pancreatic cancer 
The previously discussed hallmarks of cancer—self-sufficiency in growth signals, 
insensitivity to growth-inhibitory factors, unlimited replicative potential, evasion of 
apoptosis, angiogenesis, and metastasis—identify the biological processes which must be 
genetically altered to generate a transformed pancreatic cell (Hanahan & Weinberg, 2000). 
www.intechopen.com
 Pancreatic Cancer – Molecular Mechanism and Targets 288 
As the discussion of cancer cell origins hopefully made clear, however, differentiated 
quiescent cells can sometimes acquire some of these characteristics during normal organism 
functioning. If such a facultative progenitor cell initiates pancreatic cancer, then genetic 
alterations likely affect the remaining uncompromised biological systems. This section will 
argue that a major consequence of genetic mutations in pancreatic cancer is accelerating G1 
progression and disrupting Restriction point control via deregulation of the cell cycle 
machinery. Proliferative control mechanisms can be disrupted in one of two ways: 1) 
Directly, by mutation of the machinery itself; 2) Indirectly, by disruption of upstream 
signaling pathways. As is always the case with cancer, enhanced genetic instability 
underlies accumulation of transforming mutations (Negrini, et al., 2010). One such genetic 
alteration occurring very early in pancreatic cancer is telomere abnormalities (Gisselsson, et 
al., 2001, Hong, et al., 2011, Kobitsu, et al., 1997, van Heek, et al., 2002).  
5.1 Telomere abnormalities 
Most cells have limited replicative potential determined by the rate of telomere loss 
(Hornsby, 2005). Chromosome ends present a special challenge to DNA replication, since 
the directionality of DNA polymerase and the subsequent removal of RNA primers means 
that genetic material is lost each round unless special precautions are taken (Gilson & Géli, 
2007). The resulting ends become “sticky” and potentially interact, resulting in aberrant 
recombination events and chromosome breakage during anaphase. This repeated cycle of 
chromosome fusion and breakage has been implicated in genetic abnormalities such as 
amplifications and deletions that contribute to transformation (Murnane, 2010). 
Chromosome ends are therefore protected by TTAGGG repeats which are enzymatically 
added to the ends by an enzyme called telomerase (Osterhage & Friedman, 2009).  
In many types of cancer telomerase is inappropriately activated in order to maintain the 
ends and prevent cell cycle exit (Artandi & DePinho, 2010). In the case of pancreatic cancer, 
however, telomere shortening appears to be a very early event in the formation of PanIN 
precursor lesions (Bogenrieder & Herlyn, 2003, Hong, et al., 2011). It results in greatly 
enhanced genomic instability that causes global genome rearrangements and facilitates 
accumulation of subsequent point mutations. Telomerase appears to be re-activated if these 
lesions progress and become ductal adenocarcinomas, perhaps to reduce genome 
rearrangements that threaten cancer cell viability (Hong, et al., 2011). The early onset of 
telomere shortening in pancreatic cancer suggests that the affected cell may not be subject to 
limited replicative potential, further evidence supporting a stem cell origin for the disease. 
5.2 Mutational activation of ras signaling  
K-ras appears to be the major proto-oncogene mutated in pancreatic cancer (~90% of cases), 
acting as an initiating event occurring very early in pre-cancerous lesions (Caldas & Kern, 
1995, Moskaluk, et al., 1997). The high likelihood of K-ras disruption strongly suggests that it 
is also disrupted in the remaining 10% of cases, albeit by different mechanisms. As will be 
discussed below, work from our laboratory on the CDK inhibitor p27kip1 has identified a 
novel pathway by which this could occur. Ras is a member of the GTPase family that plays a 
key role in receiving and transmitting extracellular signals to the nucleus, where they 
modulate gene expression and make cell fate decisions (Takuwa & Takuwa, 2001). It is 
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recruited to the membrane upon activation of receptor tyrosine kinases by association with 
GRB2-SOS (Chang, et al., 2003). This complex activates Ras by converting it to the GTP-
bound form, which initiates signal transmission via activation of the Map kinase cascade 
(see Figure 4) (Coleman, et al., 2004). The ability to turn off signaling is crucial, so Ras is a 
GTPase that can hydrolyze GTP to GDP (Bernards, 2003). Ras regulation therefore centers in 
large part on controlling GTP hydrolysis and GDP dissociation to achieve the proper degree 
and duration of downstream signaling.  
Sequencing of primary pancreatic cancer samples revealed that K-ras mutations tend to 
target codon 12 and inactivate GTPase activity (Caldas & Kern, 1995, Moskaluk, et al., 1997) . 
The resulting K-ras-GTP continues downstream signaling in the absence of upstream 
effectors and in spite of inhibitory signals. Although mutated K-ras is in its active GTP 
bound form, it may still need to be localized to the membrane in order to initiate 
downstream signaling (Weise, et al., 2011). Thus, other regulatory events help determine the 
level and duration of downstream signaling from mutated K-ras. For this reason, additional 
mutations affecting Ras regulation are also observed. These results illustrate how disrupting 
key signaling pathways requires the synergistic effects of multiple genetic disruptions due 
to fail-safe mechanisms and checkpoints that have evolved to prevent cell transformation 
(Hanahan & Weinberg, 2000).  
Signaling pathways affected to be activated by mutant K-ras are the Raf-Map kinase 
cascade, PI3K-AKT, and RalGDS, with each making a distinct contribution to development 
of the transformed cell (Calvo, et al., 2010). As discussed above, Ras/Map kinase plays a key 
role in promoting cell cycle re-entry and progression. PI3K-AKT is involved in cell survival, 
while RalGDS is one of several Ras-regulated guanine-nucleotide exchange factors that 
activates Ral A and B GTPases (Carnero, et al., 2008, Ferro & Trabalzini, 2010). Ral proteins 
regulate key cellular processes such as endocytosis, exocytosis, and actin organization, as 
well as contributing to regulation of gene expression (Carnero, et al., 2008, Ferro & 
Trabalzini, 2010). A number of additional genetic disruptions appear to be required for 
mutant K-ras induced transformation. Of particular interest is excess cyclin D1, itself a 
downstream target of Ras that is commonly mutated in the disease state (Fry, et al., 2008, 
Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a). Given the pleotropic effects of Ras 
signaling, further work is required to completely describe its contribution to transformation. 
5.3 Mutational activation of other proto-oncogenic signaling pathways  
The Ras/Map kinase pathway is only one of twelve core signaling pathway disrupted in the 
disease (Jones, et al., 2008). It is beyond the scope of this chapter to discuss each pathway in 
detail, other than to note that the consequences of their disruption likely mimic, enhance, or 
synergize with K-ras mutations to drive transformation and cancer progression. 
Involvement of Notch and hedgehog signaling deserves special mention, as these critical 
pathways are best known for maintaining cells in an undifferentiated state during 
development (Kelleher, 2011, Ristorcelli & Lombardo, 2010). In the adult organism, these 
pathways are involved in tissue homeostasis via maintenance of tissue stem cell 
populations. During injury, there is a transient induction and expansion of Hedgehog or 
Notch dependent stem cell populations to replace damaged or lost cells (Siveke, et al., 2008). 
In the mature pancreas, Notch signaling is restricted to centroacinar cells, suggesting they 
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might be the originating cancer cell (Miyamoto, et al., 2003). Support for this idea comes 
from mice with conditional knockout of the PTEN tumor suppressor in the pancreas, which 
develop ductal metaplasias resulting from expansion of CACs (Hill, et al., 2010). Similarly, 
expression of Notch components is elevated in PanIN lesions and invasive cancer (Wang, 
Zhiwei, et al., 2011b). Mutational activation of these pathways cooperates with K-ras 
mutations throughout development of pancreatic cancer, from generating precancerous 
PanIN lesions to involvement in tumor maintenance and metastases. Both the Hedgehog 
and Notch pathways appear to be disrupted by ligand overexpression rather than direct 
mutational targeting of pathway constituents. 
5.4 Mutational inactivation of tumor suppressors 
Temporal disruption of specific tumor suppressors is also observed in the PanIN 
progression model and again seem to converge on enhancing genomic instability and/or 
disrupting Restriction point control. For most cancers, mutations in the tumor suppressor 
p53 or one of its regulatory components (e.g. ARF) are present in the majority of cases 
(Sherr, C. J., 1998). p53 is the central transcriptional regulator responding to all types of cell 
stress. It induces expression of proteins to stop the cell cycle and determine if damage can be 
repaired; if not, it helps activate the apoptotic pathway (Muller, et al., 2011). Inactivation of 
this pathway is so common because it contributes to cell immortalization and allows 
accumulation of further genetic mutations (Hanahan & Weinberg, 2000). It is somewhat 
curious that p53 mutations are observed in only 50% of pancreatic cancers, and they tend to 
occur later in the progression model (Morton, et al., 2011). This observation (as was the case 
with telomere shortening), suggests the initiating cell might already be immortal or at least 
more resistant to apoptosis. Mutation of p53 could therefore contribute something else to 
development of pancreatic cancer. A central target of p53 is p21cip1, a CDK2 inhibitor that 
blocks cell cycle progression in G1 phase (Doucas, et al., 2006, el-Deiry, 1998). Thus, its 
mutation could enhance the rate of G1 progression and passage through the Restriction 
point.  
The p16INK4A CDK inhibitor specifically targets cyclin D and is inactivated in >80% of 
pancreatic cancers (Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a). This suggests 
enhanced activity of cyclin D-CDK4/6 complexes makes an important contribution to 
development of pancreatic cancer, consistent with the common overexpression of cyclin D1 
(Fry, et al., 2008). The mechanism of p16 loss is diverse, involving homozygous deletion 
(40%), intragenic mutation followed by inactivation of the second allele (40%), and 
methylation inactivation of the promoter (10-15%) (Gansauge, et al., 1997, Kornmann, 
Marko, et al., 1998a). The locus encoding for this gene is unique in that it also encodes for 
p14ARF, an alternative reading frame gene product that plays a key role in activating p53 by 
preventing its degradation (Sherr, C. J., 2001). Specific inactivation of p16 plays a greater 
role in pancreatic cancer than loss of ARF function, as mutations have been characterized 
that compromise p16 while leaving ARF intact (Jeong, et al., 2005, Maitra, A & Hruban, 
2008). As discussed above, this observation is intriguing since loss of ARF is the major 
alternative pathway for inactivating p53 (Sherr, C. J., 2001). Preferential targeting of p16 
further illustrates the importance of compromising Restriction point control via disruption 
of the cyclins and CDKs controlling G1 progression.  
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Other identified mutations support this idea. SMAD4 is a cytoplasmic transcription factor 
involved in G1 cell cycle arrest mediated by the TGFB pathway (Yang, Guan & Yang, 2010). 
It is mutated ~50% of pancreatic cancers (Blackford, et al., 2009). Its normal function involves 
association with SMAD2/3 and translocation into the nucleus where it mediates 
transcriptional activation of growth inhibitory genes like p27kip1 (Yang, Guan & Yang, 
2010). Again, these results can be interpreted as modulating the cell cycle machinery 
controlling G1 progression and the Restriction point.  
5.5 Animal models of pancreatic cancer 
Genetically engineered mice have been developed in which genes of interest can be 
expressed in the pancreas using organ-specific promoter constructs. Mutant K-ras 
expression in the mature ductal epithelium gave little phenotype and no precursor lesions, 
suggesting these are not the cells of origin (Brembeck, et al., 2003). However, the K-ras 
mutation was able to induce carcinogenesis when combined with chemically induced 
pancreatic injury (Guerra, et al., 2007). Under these conditions mature differentiated cells are 
directed to re-enter the cell cycle to replace lost cells. This result strongly supports the idea 
of a stem cell or facultative progenitor cell as the originating cancer cell.  
In contrast, mice developed a spectrum of precursor lesions when oncogenic K-ras was 
expressed from its endogenous promoter in the developing pancreas (Guerra, et al., 2007). 
Only 10% developed into metastatic adenocarcinoma, however, and it required a long 
latency period. Similar results were observed when mutant K-ras was specifically expressed 
during development in acinar cells under control of the elastase promoter (Hruban, et al., 
2006). Ras-induced senescence may be responsible for the lack of tumor formation, 
underscoring the importance of cooperating mutations (Dimauro & David, 2010). This 
hypothesis was confirmed by the much greater penetrance in mice with combinations of 
mutations (K-ras plus p53 or p16) (Wang, Zhiwei, et al., 2011b). Under these conditions, the 
putative cell of origin responds to mutated K-ras by differentiating along a ductal lineage 
(hence the ductal adenocarcinomas). Inactivating the tumor suppressors p16 or p53 alone 
did not give an obvious phenotype or precursor lesions, suggesting K-ras acts as an initiator 
mutation (Wang, Zhiwei, et al., 2011b). Similarly, conditional Smad4 or TGFB receptor 
deletions were not sufficient to induce mPanIN lesions or cancer, although they clearly 
cooperated with K-ras to induce pancreatic neoplasia (Bardeesy, et al., 2006).  
5.6 Centrality of disrupted restriction point control  
Altered G1 progression and Restriction point control appear to be key events in 
development of pancreatic cancer based on mutations involved and the putative cell of 
origin. The central role of cell cycle disruptions can be modeled by considering mutations in 
the context of the progression model. Greater than 90% of low-grade PanIN lesions show 
shortened telomeres, providing a mechanism for rapidly generating genetic alterations 
required for cell transformation (Hong, et al., 2011, van Heek, et al., 2002). K-ras mutation is 
one of the earliest abnormalities and is likely an initiating event, being present in 36% of 
PanIN-1A, 44% of PanIN-1B, and 87% of PanIN-2/3 precursor lesions (Caldas & Kern, 1995, 
Moskaluk, et al., 1997). That such a dramatic alteration occurs so early is interesting, since 
expressing mutated K-ras in animal models typically results in senescence or apoptosis as a 
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protective response to loss of proliferative control (Dimauro & David, 2010, Overmeyer & 
Maltese, 2011). Taken together, telomere shortening and K-ras activation point to the initial 
transformation involving a stem cell or facultative progenitor that re-enters the cell cycle in 
response to injury/tissue maintenance.  
Such cells likely already possess characteristics of cancer cells such as immortality and 
replicative potential. Thus, mutations are not required to drive cells back into the 
proliferative cycle from a quiescent state. Their predisposition to immortality means tumor 
suppressors like p53 or ARF need not be immediately inactivated, while telomere 
shortening is tolerated and beneficial since it induces genomic instability. What then is the 
limiting factor in transformation and expansion of the cancer cell? It is becoming 
increasingly apparent that the kinetics of stem cell cycling are quite different that those of 
somatic cells in culture (Nacusi & Sheaff, 2007, Neganova & Lako, 2008). Although they 
have limitless replicative capacity, stem cells generally take much longer to duplicate (i.e. 
doubling time of days). If the initiating cell in pancreatic cancer replicates so slowly, a major 
consequence of K-ras mutation might be to speed up the duplication rate. The overall time 
required for cell cycling is determined in large part by the rate of G1 progression (the 
longest phase of the cell cycle), so mutations would be expected to speed up this process 
and ensure passage through the Restriction point (Salomoni & Calegari, 2010).  
One way mutant K-ras might increase the proliferative rate is by increasing activity of cell 
cycle components involved in the rate limiting step(s) for G1 progression (see Figure 7). 
Experiments in tissue culture cells suggest that overexpressing G1 cyclins or otherwise 
increasing CDK activity (e.g. blocking its inhibition) can accelerate G1 phase (Roberts & 
Sherr, 2003, Sherr, C. J. & Roberts, 1999). Similarly, cyclin D1 is commonly overexpressed 
and its inhibitor p16 inactivated in pancreatic cancers (Chen, Jinyun, et al., 2009b, Fry, et al., 
2008, Gansauge, et al., 1997, Kornmann, Marko, et al., 1998a, Lee, et al., 2009, Schutte, et al., 
1997). Experiments using pancreatic cancer cell lines show blocking activity of excess cyclin 
D retarded cell growth and reduce their ability to generate tumors in nude mice (Kornmann, 
M., et al., 1998b). Various drugs (e.g. celecoxib, green tea constituents) displaying efficacy 
against pancreatic cancer cell lines often target excess cyclin D (Tseng, et al., 2002). 
Disruptions during the early stage of mitogen dependent cell cycle progression leading up 
to the Restriction point therefore appear critical to development of pancreatic 
adenocarcinoma. One obvious consequence would be to enhance cyclin D/CDK4/6 activity, 
suggesting Rb phosphorylation and inactivation is crucial to transformation of the initiating 
cell. While these early events could certainly accelerate G1 progression, the transition to 
mitogen independence reflected in the Restriction point is also likely to be rate limiting. 
Thus, cyclin E-CDK2 activity is likely to be enhanced given its role in this process (see 
Figure 7) (Sheaff & Roberts, 1998). Evidence in support of this hypothesis comes from 
analyzing the contribution of K-ras mutation on proliferation of pancreatic cancer cell lines.  
Using small molecule inhibitors of MEK, Gysin et al. found that cells arrested in G1 due to 
increased expression of the tumor suppressor p27kip1 (Gysin, et al., 2005). As a 
consequence, CDK2 was inhibited, Rb was not phosphorylated, and the E2F activity 
required for G1 progression was absent. These results indicate that inhibiting p27 expression 
is a major role of K-ras mutation, thereby enhancing CDK2 activity and accelerating G1 
progression. As described below, we propose that an additional rationale for decreasing p27 
is to ensure continued activation of the mutated K-ras pathway driving transformation. In 
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contrast, MEK inhibition had little effect on CDK4 activity, suggesting K-ras mutation is not 
responsible for effects on early G1 progression (Gysin, et al., 2005). The obvious candidates 
for affecting this period are the aforementioned cyclin D1 overexpression and inactivation of 
p16. It should be noted that there are also mechanisms through which increasing cyclin D1 
levels could contribute to enhanced CDK2 activity. Additional support for the importance of 
CDK2 comes from analysis of OGF signaling, which negatively regulates progression of 
pancreatic cancer (Fan, et al., 2008). It does so by inducing expression of the CDK2 inhibitor 
p21cip1, further evidence that accelerating G1 progression is a key step in disease 
development (Fan, et al., 2008).  
 
Fig. 6. Ras/Map Regulation by p27. Mitogen stimulation of the Ras/Map pathway leads to 
the phosphorylation and export of p27 from the nucleus. This exported P-p27 binds 
competitively for Grb2 against SOS. The dissociation of the Grb2/SOS complex leads to the 
down regulation of the Ras/Map pathway signal. 
In addition to its effects on early G1 phase, overexpressed cyclin D1 is known to bind and 
sequester p27 (Sherr, C. J. & Roberts, 1999). This would indirectly enhance CDK2 activity 
and hence progression through the Restriction point. Work in our lab has shown that p27 
also functions in a negative feedback loop regulating Ras activation by GRB2 (see Figure 6) 
(Moeller, et al., 2003). If cyclin D1 were to sequester p27, this negative feedback would be 
disrupted, thereby contributing to sustained K-ras signaling and accelerated cell cycle  
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Fig. 7. E2F Activation and Positive Feedback. Mitogen stimulation leads to the 
phosphorylation and removal of the cell cycle regulating protein Rb from the E2F-Rb 
complex. E2F goes on to activate cyclin E, whose complex with CDK2 further activates more 
E2F by Rb phosphorylation. This self-sustained postive feedback marks the transition from 
mitogen stimulated to self-sustained cell cycle progression. 
progression. We have recently investigated this possibility in breast cancer cells (which often 
overexpress cyclin D1) and found that it preferentially sequestered the phosphorylated p27 
that is exported to inhibit GRB2 (submitted). We are now investigating whether the excess 
cyclin D1 in pancreatic cancer cell lines causes a similar disruption in p27 regulation of the 
Ras pathway. These observations could help explain why cyclin D1 overexpression is 
necessary for the oncogenic effects of K-ras in pancreatic cancer (Fry, et al., 2008). Given that 
the activation of facultative progenitor cells in response to injuries is normally transient, 
inappropriate K-ras signaling could also play an important role in preventing their 
withdrawal from the cell cycle. This hypothesis is consistent with results showing that 
constitutive K-ras activation is required for maintenance of pancreatic cancer (Caldas & 
Kern, 1995). 
6. Conclusions 
Given the aggressiveness and poor prognosis of pancreatic cancer compared to many other 
forms of the disease, it is worthwhile to consider what makes it unique. This chapter 
provides an evaluation of mutational changes and disrupted biological function within the 
context of cancer hallmarks and identity of the originating cell. We argue that mutations 
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directly and indirectly affecting G1 progression and the Restriction point are crucial to 
development of the pancreatic cancer cell. This analysis will hopefully stimulate further 
research into methodologies for treating the disease by targeting disruptions in or activity of 
the relevant cell cycle machinery. This approach may offer greater specificity and fewer side 
effects than previously expected. Increasing evidence provides tantalizing clues that 
proliferative control mechanisms in normal and transformed cells might be different 
(Moeller & Sheaff, 2006). Mice lacking cyclins and CDKs, for example, can still develop 
normally (Sherr, Charles I. & Roberts, 2004). The dispensability of some cell cycle machinery 
in normal development and untransformed cells is in stark contrast to its apparent necessity 
in pancreatic cancer. Thus, the cell cycle machinery and its activities may represent viable 
therapeutic targets with unanticipated specificity for preferentially inhibiting proliferation 
of the pancreatic cancer cell. 
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